Blog

3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 2: PBNK Derived from Peripheral Blood

Release Date:

2026-04-01 18:00

HeYouSheng Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the PBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering PBMC seed stocks or directly and efficiently expanding fresh PBMCs, to ultimately obtaining NK cells with high purity and high viability.

 

He Yousheng Biology 3.0 High-Efficiency Version of HiXpan Registered trademark The NK serum-free culture kit is manufactured in strict compliance with Good Manufacturing Practice (GMP) and its production system meets relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade production and applications.

 

Sharing of NK Cell Culture Data Derived from Peripheral Blood

Sample source: Four random samples of fresh or cryopreserved PBMCs derived from peripheral blood were obtained from the HeyouSheng Biological Cell Bank.

NK kit catalog number: NK888-2L

Initial cell count: 40 million

Cell yield: 6.8 billion–8.3 billion

Training System: 2L

Harvest Purity: 90%-94%

Amplification fold: 170–260 times

 

The fluid replacement procedure is shown in the figure below:

01
01 

Fresh PBMC


 
 

Amplification factor

Purity Data

 
 


 


 


 

Raw Flow Cytometry Plot

Day 7 Day 11 Day 14

02
 

Cryopreservation of PBMC


 

Amplification factor

Purity Data


 


 


 


 

Raw Flow Cytometry Plot

Day 7

Day 11

Day 14

Previous page

3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 3: CBNK Competitor Comparison

First Release | Off-the-Shelf PBMCs Compliant with GMP and Eligible for Dual FDA–CFDA Submission Enable Compliance-Oriented iPSC Reprogramming Starting from “Zero”

Next page

Related News

HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)

Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.

HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)

The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.

(3) Batch Stability and Performance Verification | Upholding Quality, Striving for Progress While Maintaining Stability

This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.